Keryx Biopharma (KERX) Misses Q3 EPS by 19c

Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.39), $0.19 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.37 million.

At September 30, 2016, the company had cash and cash equivalents of $132.2 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
• Wyndham Hotels & Resorts, Inc. (WH) Tops Q1 EPS by 2c, Misses on Revenue; Offers FY24 EPS Guidance
• Veris Residential, Inc (VRE) Misses Q1 EPS by 1c